All changes for the tissue brain (734)
Identifier
Name
Type
Tissues
Organism
Gene
Data
Actions
DAA21
ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G2
Molecular
brain
Human
ATP6V1G2
7.0% Decrease Gene Expression Level
DAA235
transgelin 3
Molecular
brain
Human
TAGLN3
5.0% Decrease Gene Expression Level
DAA19
ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1
Molecular
brain
Human
ATP6V0D1
8.0% Decrease Gene Expression Level
DAA27
chromosome 1 open reading frame 95
Molecular
brain
Human
C1orf95
5.0% Decrease Gene Expression Level
DAA20
ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A
Molecular
brain
Human
ATP6V1A
7.0% Decrease Gene Expression Level
DAA5
actin-like 6A
Molecular
brain
Human
ACTL6A
21.0% Increase Gene Expression Level
DAA2041
Altered brain mitochondrial metabolism
Physiological
brain
Human
—
—
DAA43
chimerin (chimaerin) 1
Molecular
brain
Human
CHN1
6.0% Decrease Gene Expression Level
DAA748
Altered sleep parameters and patterns
Psychological
brain
Human
—
—
DAA138
coiled-coil domain containing 46
Molecular
brain
Human
CCDC46
86.0% Increase Gene Expression Level
DAA723
Accumulation of extracellular neuritic plaques
Physiological
brain
Human
—
—
DAA767
Cognitive executive functions decline
Psychological
brain
Human
—
—
DAA615
Alzheimer's disease
Pathological
brain
Human
—
SeriesMorbidity
DAA761
Activation threshold for long-term potentiation is increased
Psychological
brain
Human
—
—
DAA17
ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle
Molecular
brain
Human
ATP5A1
17.0% Decrease Gene Expression Level
DAA39
cholecystokinin
Molecular
brain
Human
CCK
6.0% Decrease Gene Expression Level
DAA18
ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide
Molecular
brain
Human
ATP5B
9.0% Decrease Gene Expression Level
DAA2
abl-interactor 2
Molecular
brain
Human
ABI2
18.0% Decrease Gene Expression Level
DAA8
angiomotin
Molecular
brain
Human
AMOT
10.0% Increase Gene Expression Level
DAA28
chromosome 5 open reading frame 13
Molecular
brain
Human
C5orf13
8.0% Decrease Gene Expression Level
DAA24
B-cell CLL/lymphoma 11A (zinc finger protein)
Molecular
brain
Human
BCL11A
14.0% Decrease Gene Expression Level
DAA45
Cdc2-related kinase, arginine/serine-rich
Molecular
brain
Human
CDK12
17.0% Increase Gene Expression Level
DAA95
cell division cycle 2-like 2 (PITSLRE proteins)
Molecular
brain
Human
CDC2L2
27.0% Increase Gene Expression Level
DAA741
Cerebral blood flow and glucose utilization are reduced
Physiological
brain
Human
—
—
DAA717
Dendrite regression, reduction in dendrite length
Physiological
brain
Human
—
—
Identifier | Name | Type | Tissues | Organism | Gene | Data | Actions |
---|---|---|---|---|---|---|---|
DAA21 | ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G2 | Molecular | brain | Human | ATP6V1G2 | 7.0% Decrease Gene Expression Level | |
DAA235 | transgelin 3 | Molecular | brain | Human | TAGLN3 | 5.0% Decrease Gene Expression Level | |
DAA19 | ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1 | Molecular | brain | Human | ATP6V0D1 | 8.0% Decrease Gene Expression Level | |
DAA27 | chromosome 1 open reading frame 95 | Molecular | brain | Human | C1orf95 | 5.0% Decrease Gene Expression Level | |
DAA20 | ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A | Molecular | brain | Human | ATP6V1A | 7.0% Decrease Gene Expression Level | |
DAA5 | actin-like 6A | Molecular | brain | Human | ACTL6A | 21.0% Increase Gene Expression Level | |
DAA2041 | Altered brain mitochondrial metabolism | Physiological | brain | Human | — | — | |
DAA43 | chimerin (chimaerin) 1 | Molecular | brain | Human | CHN1 | 6.0% Decrease Gene Expression Level | |
DAA748 | Altered sleep parameters and patterns | Psychological | brain | Human | — | — | |
DAA138 | coiled-coil domain containing 46 | Molecular | brain | Human | CCDC46 | 86.0% Increase Gene Expression Level | |
DAA723 | Accumulation of extracellular neuritic plaques | Physiological | brain | Human | — | — | |
DAA767 | Cognitive executive functions decline | Psychological | brain | Human | — | — | |
DAA615 | Alzheimer's disease | Pathological | brain | Human | — | SeriesMorbidity | |
DAA761 | Activation threshold for long-term potentiation is increased | Psychological | brain | Human | — | — | |
DAA17 | ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle | Molecular | brain | Human | ATP5A1 | 17.0% Decrease Gene Expression Level | |
DAA39 | cholecystokinin | Molecular | brain | Human | CCK | 6.0% Decrease Gene Expression Level | |
DAA18 | ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide | Molecular | brain | Human | ATP5B | 9.0% Decrease Gene Expression Level | |
DAA2 | abl-interactor 2 | Molecular | brain | Human | ABI2 | 18.0% Decrease Gene Expression Level | |
DAA8 | angiomotin | Molecular | brain | Human | AMOT | 10.0% Increase Gene Expression Level | |
DAA28 | chromosome 5 open reading frame 13 | Molecular | brain | Human | C5orf13 | 8.0% Decrease Gene Expression Level | |
DAA24 | B-cell CLL/lymphoma 11A (zinc finger protein) | Molecular | brain | Human | BCL11A | 14.0% Decrease Gene Expression Level | |
DAA45 | Cdc2-related kinase, arginine/serine-rich | Molecular | brain | Human | CDK12 | 17.0% Increase Gene Expression Level | |
DAA95 | cell division cycle 2-like 2 (PITSLRE proteins) | Molecular | brain | Human | CDC2L2 | 27.0% Increase Gene Expression Level | |
DAA741 | Cerebral blood flow and glucose utilization are reduced | Physiological | brain | Human | — | — | |
DAA717 | Dendrite regression, reduction in dendrite length | Physiological | brain | Human | — | — |